Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype.


Journal

ACS medicinal chemistry letters
ISSN: 1948-5875
Titre abrégé: ACS Med Chem Lett
Pays: United States
ID NLM: 101521073

Informations de publication

Date de publication:
14 Feb 2019
Historique:
received: 16 11 2018
accepted: 27 12 2018
entrez: 21 2 2019
pubmed: 21 2 2019
medline: 21 2 2019
Statut: epublish

Résumé

As universal heterodimer partners of many nuclear receptors, the retinoid X receptors (RXRs) constitute key transcription factors. They regulate cell proliferation, differentiation, inflammation, and metabolic homeostasis and have recently been proposed as potential drug targets for neurodegenerative and inflammatory diseases. Owing to the hydrophobic nature of RXR ligand binding sites, available synthetic RXR ligands are lipophilic, and their structural diversity is limited. Here, we disclose the computer-assisted discovery of a novel RXR agonist chemotype and its systematic optimization toward potent RXR modulators. We have developed a nanomolar RXR agonist with high selectivity among nuclear receptors and superior physicochemical properties compared to classical rexinoids that appears suitable for

Identifiants

pubmed: 30783504
doi: 10.1021/acsmedchemlett.8b00551
pmc: PMC6378677
doi:

Types de publication

Journal Article

Langues

eng

Pagination

203-208

Déclaration de conflit d'intérêts

The authors declare no competing financial interest.

Références

Int J Toxicol. 2010 Mar-Apr;29(2):157-64
pubmed: 20335511
J Med Chem. 2017 Jul 13;60(13):5235-5266
pubmed: 28252961
Expert Opin Drug Discov. 2012 Nov;7(11):1003-16
pubmed: 22954251
J Med Chem. 2015 Jan 22;58(2):912-26
pubmed: 25486327
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2731-7
pubmed: 17008586
ACS Med Chem Lett. 2012 Apr 09;3(5):427-32
pubmed: 24900488
Expert Opin Ther Pat. 2014 Apr;24(4):443-52
pubmed: 24456080
Science. 2012 Mar 23;335(6075):1503-6
pubmed: 22323736
Pharmacol Rev. 2006 Dec;58(4):760-72
pubmed: 17132853
Cutis. 2017 Feb;99(2):E30-E34
pubmed: 28319634
Curr Top Med Chem. 2017;17(6):631-662
pubmed: 27320335
N Engl J Med. 1999 Apr 8;340(14):1075-9
pubmed: 10194237
Nat Neurosci. 2011 Jan;14(1):45-53
pubmed: 21131950
Curr Top Med Chem. 2016 Jun 16;:
pubmed: 27320330
Semin Oncol. 2016 Feb;43(1):49-64
pubmed: 26970124
J Med Chem. 2013 Mar 14;56(5):1865-77
pubmed: 23391145
Nat Rev Drug Discov. 2007 Oct;6(10):793-810
pubmed: 17906642
J Biol Chem. 2014 Jan 10;289(2):814-26
pubmed: 24187139
Bioorg Med Chem Lett. 2017 Mar 1;27(5):1193-1198
pubmed: 28169169

Auteurs

Pascal Heitel (P)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Leonie Gellrich (L)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Lena Kalinowsky (L)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Jan Heering (J)

Project Group Translational Medicine and Pharmacology TMP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Theodor-Stern-Kai 7, D-60596 Frankfurt, Germany.

Astrid Kaiser (A)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Julia Ohrndorf (J)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Ewgenij Proschak (E)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Daniel Merk (D)

Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, 60438 Frankfurt, Germany.

Classifications MeSH